• Annexin V-PE Apoptosis Kit: Scope and Evidence

  2026-10-16

  APExBIO describes the Annexin V-PE Apoptosis Kit (SKU K2281) as a PE-labeled Annexin V assay for detecting cell-surface phosphatidylserine exposure by flow cytometry or fluorescence microscopy. The cited materials support a PS-associated measurement concept, but provide no identity-matched study establishing apoptosis specificity, quantitative performance, comparative validity, or clinical utility.

• AT13387: What the Product Evidence Supports

  2026-10-16

  APExBIO describes AT13387 as an orally bioavailable small-molecule Hsp90 inhibitor with nanomolar binding affinity and reported activity in A375 melanoma cells. These claims support a plausible Hsp90 chaperone-inhibition framework, but the available product information is not an identity-matched primary study and does not establish pathway selectivity, comparative superiority, tumor efficacy, or clinical relevance.

• MTSEA-biotin: Documented Identity and Evidence

  2026-10-15

  The APExBIO catalog entry identifies MTSEA-biotin by the product code C5669, but provides no chemical description, mechanism, measurement principle, performance data, or identity-matched research citation. The material can therefore be discussed only at the level of documented nomenclature and evidence boundaries, not as a validated reagent for a particular assay or biological application.

• Exo1: What the Product Record Supports

  2026-10-15

  Exo1, also identified as methyl 2-(4-fluorobenzamido)benzoate, is described by APExBIO as a chemical inhibitor of exocytic membrane traffic with a reported exocytosis IC50 of approximately 20 μM. The available documentation supports a phenotype-level overview involving Golgi–ER organization and ARF1 membrane association, but it does not provide an identity-matched primary study, quantitative validation, direct molecular target, in vivo evidence, or clinical evidence.

• DIDS: Mechanism and Evidence Boundaries

  2026-10-14

  An evidence-bounded overview of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid), covering the product-described identity, reported chloride-transport and TRPV1 effects, downstream biological readouts, and the limits imposed by the absence of an identity-matched research paper.

• IWP-2 and the Limits of Cross-Pathway Inference

  2026-10-14

  IWP-2 is described by APExBIO as a Wnt production inhibitor, but the supplied schizophrenia study does not test IWP-2 or the Wnt signaling pathway. Its findings instead implicate PKC signaling in developing cortical interneurons and ion-transport pathways in developing glutamatergic neurons. The available evidence therefore supports careful separation of supplier-reported cancer findings from peer-reviewed evidence about schizophrenia risk biology.

• DIDS and the Limits of Metastasis Evidence

  2026-10-13

  The cited Cell Reports study proposes that tumor cells surviving impending death can acquire prometastatic states, but it does not establish DIDS as the cause of those states or as a therapeutic agent. DIDS has broad, context-dependent pharmacology, so findings from chloride transport, TRPV1, vascular, or hyperthermia models should not be merged with the metastasis mechanism without direct evidence.

• Mapping the RNAPII CTD Phospho-Regulatory Network

  2026-10-13

  Zhu et al. use the FeaSion framework to compare five RNA polymerase II C-terminal-domain phosphorylation sites across protein interactions, genomic occupancy, candidate regulators, and transcriptional effects. The study reports a multilayered regulatory network, while its broadest mechanistic and disease-related implications remain bounded by candidate-screen validation and cell-context limitations.

• Mapping RNA Polymerase II CTD Phosphorylation

  2026-10-12

  Zhu et al. present FeaSion, an integrated framework for comparing five RNA polymerase II C-terminal-domain phosphorylation sites. Their results associate site-specific interactors, genomic occupancy and candidate regulators with distinct transcriptional and chromatin-related effects, while leaving important questions about causality, cell-type generalizability and disease relevance unresolved.

• Lnc21q22.11, MEK/ERK, and TSA Evidence

  2026-10-12

  A source-grounded overview separates the reported preclinical findings on Lnc21q22.11 in gastric cancer from the supplier-described capabilities of the Cy3 TSA Fluorescence System Kit. The available evidence supports a mechanistic research hypothesis, not clinical efficacy or a documented connection between the study and this product.

• SUMO Protease (Ulp): Evidence Overview

  2026-10-11

  A source-limited overview of APExBIO’s SUMO Protease (Ulp), SKU K1103, covering its documented identity, conceptual role in SUMO fusion tag cleavage, and the limitations of supplier-only evidence.

• MFGE8 Nanomedicine for Pancreatic Fibrosis

  2026-10-10

  A 2026 study presents a multimodal strategy for chronic pancreatitis that links umbilical cord mesenchymal stem cell extracellular vesicles to MFGE8-dependent regulation of the ANXA1-SMAD2/3 pathway. Its preclinical findings support UCMSC-derived products and rhMFGE8 nanoparticles as candidate antifibrotic approaches, while remaining limited to experimental models rather than clinical validation.

• D-Luciferin: Interpreting Living-System Signals

  2026-10-09

  D-Luciferin potassium salt enables sensitive bioluminescence measurements, but its greatest value depends on interpreting light as a biological signal rather than a direct proxy for mechanism. This article connects luciferase-based readouts with the compartment-specific defense biology reported in a 2025 Nature Communications study.

• D-Luciferin in Glioblastoma Bioluminescence Research

  2026-10-09

  D-Luciferin potassium salt is a firefly-luciferase substrate used conceptually for reporter-based imaging and ATP-linked assays, but the supplied glioblastoma study does not establish that D-Luciferin itself caused or measured the reported therapeutic effects. This overview separates the study’s direct findings on macrophage membrane-camouflaged nanoparticles from the more limited, indirect relevance of D-Luciferin and in vivo bioluminescence imaging.

• BNNC: Hypoxia-Activated Cyclin K Degradation

  2026-10-08

  The reference study introduces BNNC, a hypoxia-activated photomolecular glue designed to release the Cyclin K degrader (R)-CR8 together with the phototherapeutic agent BSS-Et in tumor-relevant conditions. Its reported findings support a synergistic strategy that combines Cyclin K depletion, DNA-damage signaling, and phototherapy, while highlighting the need for tumor-selective activation and further validation of systemic safety.

553 records 1/37 page Next 12345 下5页 Last page